Newsroom

Keep up with our latest news.

July 2022

Elevation Oncology Expands Pipeline through Exclusive Licensing of EO-3021 (SYSA1801), a Clinical Stage Anti-Claudin18.2 Antibody Drug Conjugate, From CSPC Pharmaceutical Group

All
Press Releases

August 04, 2022

Press Releases

Elevation Oncology Reports Second Quarter 2022 Financial Results and Highlights Recent Company Progress Read More

July 28, 2022

Press Releases

Elevation Oncology Secures $50 Million Loan Facility with K2 HealthVentures Read More

July 28, 2022

Press Releases

Elevation Oncology Expands Pipeline through Exclusive Licensing of EO-3021 (SYSA1801), a Clinical Stage Anti-Claudin18.2 Antibody Drug Conjugate, From CSPC Pharmaceutical Group Read More

May 26, 2022

Press Releases

Elevation Oncology to Present Initial Seribantumab Proof-of-Concept Data from Phase 2 CRESTONE Study in Patients with Tumors Harboring NRG1 Fusions at ASCO 2022 Read More

May 25, 2022

Press Releases

Elevation Oncology Announces FDA Fast Track Designation Granted to Seribantumab for the Tumor-Agnostic Treatment of Solid Tumors Harboring NRG1 Gene Fusions Read More

May 05, 2022

Press Releases

Elevation Oncology Reports First Quarter 2022 Financial Results and Highlights Recent Company Progress Read More

Pages: 12345Last Page

Investor Resources

Follow our journey with our latest Investor Resources

Press Releases

Read the latest News Releases for Investors

Events

Browse the calendar to view Investor related events and announcements. Webcasts and presentations that have been archived are available by viewing historical event details.

SEC Filings

Review all of Elevation's SEC filings

Track our progress

Check back often for our latest insights, or sign up for our mailing list to receive the have the latest news and publications from Elevation Oncology delivered to your inbox.